Active substanceAmlodipineAmlodipine
Similar drugsTo uncover
  • Amlovas®
    pills inwards 
  • Amlodak
    pills inwards 
  • Amlodigamma
    pills inwards 
  • Amlodipine
    pills inwards 
    MEDISORB, CJSC     Russia
  • Amlodipine
    pills inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Amlodipine
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Amlodipine
    pills inwards 
    LEKFARM, SOOO     Republic of Belarus
  • Amlodipine
    pills inwards 
    Hemofarm AD     Serbia
  • Amlodipine
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Amlodipine
    pills inwards 
  • Amlodipine
    pills inwards 
  • Amlodipine
    pills inwards 
  • Amlodipine
    pills inwards 
       
  • Amlodipine
    pills inwards 
    ROSFARM, LLC     Russia
  • Amlodipine
    pills inwards 
    ZIO-HEALTH, JSC     Russia
  • Amlodipine
    pills inwards 
    OZONE, LLC     Russia
  • Amlodipine Alkaloid
    pills inwards 
    Alkaloid, JSC     Macedonia
  • Amlodipine Zentiva
    pills inwards 
    Zentiva c.s.     Czech Republic
  • Amlodipine Cardio
    pills inwards 
  • Amlodipine Cardio
    pills inwards 
  • Amlodipine Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Amlodipine-Agio
    pills inwards 
  • Amlodipine-Biocom
    pills inwards 
    BIOKOM, CJSC     Russia
  • Amlodipine-Borimed
    pills inwards 
  • Amlodipine-3T
    pills inwards 
  • Amlodipine-Prana
    pills inwards 
    PRANAFARM, LLC     Russia
  • Amlodipine-Teva
    pills inwards 
  • Amlodipine-Chaikafarma
    pills inwards 
  • Amlodipharm®
    pills inwards 
  • Amlocard-Sanovel
    pills inwards 
  • Amlong
    pills inwards 
  • Amlonorm
    pills inwards 
    Adifarm, EAD     Bulgaria
  • Amrorus®
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Amlotop
    pills inwards 
    MAKIZ-PHARMA, LLC     Russia
  • Vero-Amlodipine
    pills inwards 
    VEROPHARM SA     Russia
  • Calcheck®
    pills inwards 
  • Cardilopin®
    pills inwards 
  • Karmagip®
    pills inwards 
  • Corvadil®
    pills inwards 
  • Cordy Cor®
    pills inwards 
    Aktavis, AO     Iceland
  • Norvasc®
    pills inwards 
    Pfizer GmbH     Germany
  • Normodipine®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Stamlo® M
    pills inwards 
  • Dosage form: & nbspPills
    Composition:

    one 5 mg tablet contains: active substance amlodipine besylate in terms of amlodipine - 5 mg;

    auxiliary substances: lactose monohydrate (sugar milk) - 67.0 mg, corn starch - 6.5 mg, povidone-K25 - 2.85 mg, microcrystalline cellulose - 16.0 mg, magnesium stearate - 0.7 mg.

    one 10 mg tablet contains: active substance amlodipine besylate in terms of amlodipine - 10 mg;

    auxiliary substances: lactose monohydrate (sugar milk) - 134.0 mg, corn starch - 13.0 mg, povidone-K25 - 5.7 mg, microcrystalline cellulose - 32.0 mg, magnesium stearate - 1.4 mg.

    Description:

    Tablets are white or almost white with a risk on one side and a chamfer on both sides. Light marble is allowed.

    Pharmacotherapeutic group:blocker of "slow" calcium channels
    ATX: & nbsp

    C.08.C.A.01   Amlodipine

    Pharmacodynamics:

    Derivhydropyridine derivative - blocker of "slow" calcium channels II generation, has an antianginal and hypotensive effect. Linking with dihydropyridine receptors, blocks calcium channels, reduces the transmembrane transition of calcium ions into the cell (mostly in smooth muscle cells of blood vessels, rather than in cardiomyocytes). Antianginal action is due to the expansion of coronary and peripheral arteries and arterioles: with angina decreases severity of myocardial ischemia; expanding peripheral arterioles, reduces the overall peripheral vascular resistance, reduces preload on the heart, reduces the need for myocardium in oxygen. Expanding the main coronary arteries and arterioles in unchanged and ischemic zones of the myocardium, increases the flow of oxygen into the myocardium (especially with vasospastic angina); prevents the development of constriction of the coronary arteries (including caused by smoking). In patients with angina, a single daily dose increases the time of exercise, slows the development of angina pectoris and the "ischemic" depression of the segment ST, reduces the incidence of angina attacks and consumption of nitroglycerin.

    Has a long-term dose-dependent hypotensive effect. Hypotensive effect is caused by a direct vasodilating effect on smooth muscle vessels. In hypertension, a single dose provides a clinically significant decrease in blood pressure (BP) for 24 hours (in the patient's position "lying" and "standing"). Does not cause a sharp decrease in blood pressure, a decrease in exercise tolerance, a fraction of the ejection of the left ventricle. Reduces the degree of myocardial hypertrophy of the left ventricle, has antiatherosclerotic and cardioprotective action in ischemic heart disease (CHD). Does not affect the contractility and conductance of the myocardium, does not cause a reflex increase in the heart rate (HR), inhibits platelet aggregation, increases the rate of glomerular filtration, has a weak natriuretic effect. When diabetic nephropathy does not increase the severity of microalbuminuria. Does not have adverse effects on the metabolism and lipids of blood plasma. The time of onset of the effect is 2-4 hours, the duration of the effect is 24 hours.

    Pharmacokinetics:

    After oral administration amlodipine is slowly absorbed from the gastrointestinal tract. The average absolute bioavailability is 64%, the maximum serum concentration is observed after 6-9 hours. The concentration of stable equilibrium is reached after 7 days of therapy. Food does not affect the absorption of amlodipine. The average volume of distribution is 21 l / kg body weight, indicating that most of the drug is in the tissues, and relatively less in the blood. Most of the drug in blood (95%), binds to blood plasma proteins.

    Amlodipine undergoes a slow but extensive metabolism (90%) in the liver with the formation of inactive metabolites, has the effect of a "first pass" through the liver. Metabolites do not have significant pharmacological activity.

    After a single oral intake, the half-life period (T1 / 2) varies from 31 to 48 hours, with the repeated appointment of T1 / 2 is approximately 45 hours. About 60% of the ingested dose is excreted urine mainly in the form of metabolites, 10% unchanged, and 20-25% with feces, as well as with breast milk.The total clearance of amlodipine is 0.116 ml / s / kg (7 ml / min / kg, 0.42 l / h / kg).

    In elderly patients (over 65 years of age) the excretion of amlodipine is slowed down (T1 / 2 65h) in comparison with young patients, however this difference has no clinical significance. In patients with hepatic insufficiency, an extension of T1 / 2, and with a long appointment, the accumulation of the drug in the body will be higher (T1 / 2 to 60 hours). Renal failure does not significantly affect the kinetics of amlodipine. The drug penetrates the blood-brain barrier. When hemodialysis is not removed.

    Indications:

    Arterial hypertension (monotherapy or in combination with other antihypertensive agents).

    Stenocardia of tension, vasospastic angina (Prinzmetal angina)

    Contraindications:

    - increased sensitivity to amlodipine and other dihydropyridine derivatives;

    - severe arterial hypotension;

    - collapse, cardiogenic shock;

    - unstable angina (with the exception of Prinzmetal angina)

    - pregnancy and lactation;

    - age to 18 years (efficacy and safety not established).

    Carefully:

    Carefully: impaired liver function, weakness syndrome sinus node (pronounced bradycardia, tachycardia), chronic heart failure in the stage of decompensation, mild or moderate degree of arterial hypotension, aortic stenosis, mitral stenosis, hypertrophic obstructive cardiomyopathy, acute myocardial infarction (and within 1 month after), diabetes mellitus, lipid profile, advanced age.

    Pregnancy and lactation:Contraindicated.
    Dosing and Administration:

    Inside, the initial dose for treatment arterial hypertension and angina pectoris is 5 mg of the drug once a day. The maximum dose can be increased to 10 mg once a day. With hypertension, the maintenance dose can be 5 mg per day.

    When angina pectoris and vasospastic angina - 5 - 10 mg per day, once. Thin patients, patients of low height, elderly patients, patients with impaired liver function as an antihypertensive drug are prescribed in an initial dose of 2.5 mg; as an antianginal agent - 5 mg.

    There is no need for dose changes with simultaneous administration with thiazide diuretics, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors.Do not require dose changes in patients with renal insufficiency.

    Side effects:

    From the cardiovascular system: palpitations, shortness of breath, pronounced decrease in blood pressure, fainting, vasculitis, swelling (swelling of the ankles and feet), "tides" of blood to the face, rarely - rhythm disturbances (bradycardia, ventricular tachycardia, atrial flutter), chest pain, orthostatic hypotension, very rarely - development or exacerbation of heart failure, extrasystole, migraine.

    From the central nervous system: headache, dizziness, fatigue, drowsiness, mood changes, convulsions, rarely - loss of consciousness, hypnosis, nervousness, paresthesia, tremor, vertigo, asthenia, malaise, insomnia, depression, unusual dreams, very rarely - ataxia, apathy, agitation, amnesia .

    From the digestive system: nausea, vomiting, epigastric pain, rarely - increased levels of "liver" transaminases and jaundice (caused by cholestasis), pancreatitis, dry mouth, flatulence, gingival hyperplasia, constipation or diarrhea, very rarely - gastritis, increased appetite, anorexia, hyperbilirubinemia.

    From the genitourinary system: rarely - pollakiuria, painful urge to urinate, nocturia, violation of sexual function (including a decrease in potency); very rarely - dysuria, polyuria.

    From the skin: very rarely - xeroderma, alopecia, dermatitis, purpura, discoloration.

    Allergic reactions: skin itching, rash (including erythematous, maculopapular rash, urticaria), angioedema.

    From the musculoskeletal system: rarely - arthralgia, arthrosis, myalgia (with prolonged use); very rarely - myasthenia gravis.

    Other: rarely - gynecomastia, polyuricemia, increase / decrease in body weight, thrombocytopenia, leukopenia, hyperglycemia, impaired vision, diplopia, conjunctivitis, eye pain, ringing in the ears, back pain, dyspnoea, epistaxis, increased sweating, thirst; very rarely - cold sticky sweat, cough, rhinitis, parosmia, taste disorders, accommodation disorder, xerophthalmia.

    Overdose:

    Symptoms: a marked decrease in blood pressure, tachycardia, excessive peripheral vasodilation.

    Treatment: gastric lavage, the appointment of activated charcoal, maintaining the function of the cardiovascular system, monitoring the parameters of the function of the heart and lungs, elevated limb position, monitoring the volume of circulating blood and diuresis. To restore the vascular tone - the use of vasoconstrictive drugs (in the absence of contraindications to their use); to eliminate the effects of calcium channel blockade - intravenous calcium gluconate. Hemodialysis is not effective.

    Interaction:

    Inhibitors of microsomal oxidation increase the concentration of amlodipine in the blood plasma, increasing the risk of side effects, and inductors of microsomal liver enzymes reduce.

    Hypotensive effect weakens non-steroidal anti-inflammatory drugs, especially indomethacin (sodium retention and blockade of prostaglandin synthesis by the kidneys), alpha-adrenostimulants, estrogens (sodium retention), sympathomimetics.

    Thiazide and 'loop' diuretics, beta-blockers, verapamil, ACE inhibitors and nitrates increase antianginal and hypotensive effects.

    Amiodarone, quinidine, alpha 1-adrenoblockers, antipsychotic drugs (neuroleptics) and blockers of "slow" calcium channels canintensify the hypotensive effect.

    Does not affect the pharmacokinetic parameters of digoxin and warfarin.

    Cimetidine does not affect the pharmacokinetics of amlodipine.

    When combined with preparations of lithium may be increased manifestations of neurotoxicity (nausea, vomiting, diarrhea, ataxia, tremor, tinnitus).

    Calcium preparations can reduce the effect of blockers of "slow" calcium channels.

    Procainamide, quinidine and other drugs that cause lengthening of the interval QT, reinforce the negative inotropic effect and may increase risk of significant lengthening of the interval QT. Grapefruit juice can reduce the concentration of amlodipine in the blood plasma, but this decrease is so small that it does not significantly alter the effect of amlodipine.

    Special instructions:

    During the period of treatment, it is necessary to control the body weight and sodium intake, the appropriate diet.

    It is necessary to maintain dental hygiene and frequent visits to the dentist (to prevent soreness, bleeding and gingival hyperplasia). Dosage regimen for the elderly is the same as for patients of other age groups. When increasing the dose, careful monitoring of elderly patients is necessary.

    Despite the lack of "slow" calcium channels of the syndrome of "cancellation" in blockers, a gradual decrease in doses is recommended before cessation of treatment.

    Amlodipine does not affect plasma concentrations of K+, glucose, triglycerides, total cholesterol, LDL, uric acid, creatinine and uric acid nitrogen.

    Effect on the ability to drive transp. cf. and fur:

    There were no reports of the effects of amlodipine on driving or working with machinery. However, some patients may experience drowsiness and dizziness at the beginning of treatment. When they occur, the patient must observe special precautions when driving and working with machinery.

    Form release / dosage:

    Tablets 5 mg and 10 mg.

    Packaging:

    For 10, 30 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    For 10, 20, 30, 40, 50 or 100 tablets in cans of polyethylene terephthalate or cans of polymeric for medicines.

    One jar or 1, 2, 3, 4, 5, 6, 8 or 10 contour squares, together with the instructions for use, are placed in a cardboard package (pack) of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the time specified on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-000087
    Date of registration:31.05.2007
    The owner of the registration certificate:OZONE, LLC OZONE, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp02.12.2014
    Illustrated instructions
      Instructions
      Up